argenx
- Country
- ๐ง๐ชBelgium
- Ownership
- -
- Established
- 2008-01-01
- Employees
- -
- Market Cap
- $31.2B
- Website
- https://www.argenx.com/
A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Lupus Nephritis (ZL-1103-013)
- Conditions
- Lupus Nephritis
- Interventions
- Biological: efgartigimod IVOther: Placebo
- First Posted Date
- 2023-04-13
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- argenx
- Target Recruit Count
- 73
- Registration Number
- NCT05810948
- Locations
- ๐จ๐ณ
Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
๐จ๐ณAffiliated Hospital of Jining Medical University, Jining, China
๐จ๐ณLiu Zhou Works Hospital, Liuzhou, China
A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
- Conditions
- Bullous Pemphigoid
- Interventions
- Biological: efgartigimod PH20 SC
- First Posted Date
- 2023-01-12
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- argenx
- Target Recruit Count
- 64
- Registration Number
- NCT05681481
- Locations
- ๐จ๐ณ
The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
๐จ๐ณRuijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China
๐บ๐ธMedical Dermatology Specialists, Phoenix, Arizona, United States
A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-119 in Healthy Participants
- Conditions
- Healthy Volunteers
- First Posted Date
- 2023-01-04
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- argenx
- Target Recruit Count
- 112
- Registration Number
- NCT05670704
Efficacy and Safety Study of Efgartigimod in Adults with Post-COVID-19 POTS
- Conditions
- Postural Orthostatic Tachycardia Syndrome
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- argenx
- Target Recruit Count
- 53
- Registration Number
- NCT05633407
- Locations
- ๐บ๐ธ
University of California, San Diego Sulpizio Cardiovascular Center, La Jolla, California, United States
๐บ๐ธJohns Hopkins University, Baltimore, Maryland, United States
๐บ๐ธStanford Movement Disorder Center, Palo Alto, California, United States
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
- Conditions
- Active Idiopathic Inflammatory MyopathyMyositisDermatomyositisPolymyositisImmune-Mediated Necrotizing MyopathyAntisynthetase Syndrome
- Interventions
- Other: PBO
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- argenx
- Target Recruit Count
- 240
- Registration Number
- NCT05523167
- Locations
- ๐ฏ๐ต
The University of Tokyo Hospital, Tokyo, Japan
๐ฉ๐ชUniversitatsklinikum Ulm - Standort Oberer Eselsberg, Ulm, Germany
๐ฏ๐ตJuntendo University Hospital - Rheumatology, Tokyo, Japan
A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy
- Conditions
- Multifocal Motor Neuropathy (MMN)
- Interventions
- Other: Placebo
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- argenx
- Target Recruit Count
- 51
- Registration Number
- NCT05405361
- Locations
- ๐บ๐ธ
HonorHealth Neurology, Scottsdale, Arizona, United States
๐บ๐ธAustin Neuromuscular Center, Austin, Texas, United States
๐ฆ๐นMedizinische Universitat Wien (Medical University of Vienna), Vienna, Austria
Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children with Generalized Myasthenia Gravis
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Biological: Efgartigimod IV or Efgartigimod PH20 SC
- First Posted Date
- 2022-05-16
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- argenx
- Target Recruit Count
- 12
- Registration Number
- NCT05374590
- Locations
- ๐ซ๐ท
AP-HM- Hรดpital de La Timone, Marseille, France
๐ง๐ชUniversitair Ziekenhuis Antwerpen, Edegem, Belgium
๐บ๐ธAnn and Robert H Lurie Children's Hospital of Chicago - Main Hospital, Chicago, Illinois, United States
A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants with Bullous Pemphigoid
- Conditions
- Bullous Pemphigoid
- Interventions
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- argenx
- Target Recruit Count
- 98
- Registration Number
- NCT05267600
- Locations
- ๐บ๐ธ
Investigator site 121 - US0010092, Redwood City, California, United States
๐บ๐ธInvestigator site 115 - US0010157, Jackson, Mississippi, United States
๐บ๐ธInvestigator site 34 - US0010182, Houston, Texas, United States
A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults with Multifocal Motor Neuropathy
- Conditions
- Multifocal Motor Neuropathy
- Interventions
- Other: Placebo
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- argenx
- Target Recruit Count
- 54
- Registration Number
- NCT05225675
- Locations
- ๐บ๐ธ
HonorHealth Research Institute-Neuroscience Research, Maitland, Florida, United States
๐บ๐ธGeorge Washington Medical Faculty Associates, Washington, District of Columbia, United States
๐บ๐ธUniversity of South Florida Carol and Frank Morsani Center for Advanced Healthcare, Tampa, Florida, United States
Immune Response to PNEUMOVAX 23 in Healthy Adults Receiving Efgartigimod IV
- Conditions
- Healthy Volunteers
- Interventions
- Biological: EfgartigimodOther: PlaceboBiological: PNEUMOVAX 23
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- argenx
- Target Recruit Count
- 36
- Registration Number
- NCT05163834
- Locations
- ๐ณ๐ฑ
Investigator site 1, Groningen, Netherlands